EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Open Access · CC BY 4.0

Dordaviprone Maintenance After Allogeneic HCT for High‐Risk Acute Myeloid Leukemia and Myelodysplastic Neoplasm

Vijaya Raj Bhatt iD, Christopher S Wichman, Alyssa Bouska, Moataz Ellithi iD, Michael Haddadin, Javeed Iqbal, James E Talmadge, Lori J Maness, Krishna Gundabolu iD

American Journal of Hematology · 2026-09 · 101 (9) · 2288-2296

DOI: 10.1002/ajh.70428 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift American Journal of Hematology, online erschienen am 26.06.2026. Verfasst von Vijaya Raj Bhatt und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology-Oncology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska, USA. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Hematopoietic Stem Cell Transplantation, Myelodysplastic Syndromes. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Nebraska Department of Health and Human Services.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Dordaviprone is a first‐in‐class small‐molecule imipridone. In preclinical studies, it is active against leukemia cells harboring a TP53 mutation or complex karyotype and leukemia stem cells while sparing normal bone marrow cells. This study aimed to determine the safety of dordaviprone maintenance after allogeneic hematopoietic cell transplantation (HCT) for high‐risk acute myeloid leukemia (AML) and myelodysplastic neoplasm (MDS). In a Phase I trial ( n = 20), adults with high‐risk AML or MDS received escalating doses of oral dordaviprone administered weekly for up to 13 four‐weekly cycles ( ClinicalTrials.gov ID: NCT03932643). The primary objective was to determine the rate of dose‐limiting toxicities (DLTs) and grade ≥ 3 adverse events (AEs). Participants' characteristics included a median age of 68 years (range: 39–75 years) and high‐risk features such as adverse‐risk AML (50%) or very poor‐risk MDS (75%), TP53 mutations (36%), or measurable residual disease before HCT (41% of AML). A total of 10 patients (one unevaluable) received 250–500 mg weekly doses, whereas the remaining 10 patients received 625 mg weekly doses. Patients received a median of 8.5 cycles (range: 1–13) of dordaviprone. No DLTs or graft failures were noted. Grades 3–4 acute GVHD was noted in 5%. Grade ≥ 3 AEs occurred in 45% (15% related). Grade 3–4 cytopenias were infrequent: anemia (15%), neutropenia (10%), and thrombocytopenia (15%). At 2 years, relapse‐free survival and overall survival were 60% (95% confidence interval [CI]: 42%–86%) and 70% (95% CI: 53%–93%), respectively. Posttransplant dordaviprone maintenance was determined to be safe with low rates of cytopenias and promising efficacy in this high‐risk population. Trial Registration ClinicalTrials.gov identifier: NCT03932643

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myeloid, AcuteHematopoietic Stem Cell TransplantationMyelodysplastic SyndromesHumansMiddle AgedAgedAdultFemaleMaleTransplantation, HomologousAllografts

Stichwörter der Autor:innen

acute myeloid leukemiaallogeneic stem cell transplantclinical trialdordavipronemyelodysplastic syndromerelapse

Autor:innen und Institutionen

  • Division of Hematology-Oncology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska, USA.
  • Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, Nebraska, USA.
  • Department of Biostatistics, University of Nebraska Medical Center, Omaha, Nebraska, USA.
  • Department of Pathology, Microbiology, and Immunology, University of Nebraska Medical Center, Omaha, Nebraska, USA.

ORCID-Profile: Vijaya Raj Bhatt, Moataz Ellithi, Krishna Gundabolu

Förderung

  • NCI NIH HHS
  • Nebraska Department of Health and Human Services

Zitieren

APA

Bhatt, V. R., Wichman, C. S., Bouska, A., Ellithi, M., Haddadin, M., Iqbal, J., Talmadge, J. E., Maness, L. J., & Gundabolu, K. (2026). Dordaviprone Maintenance After Allogeneic HCT for High‐Risk Acute Myeloid Leukemia and Myelodysplastic Neoplasm. American Journal of Hematology, 101(9), 2288-2296. https://doi.org/10.1002/ajh.70428

Vancouver

Bhatt VR, Wichman CS, Bouska A, Ellithi M, Haddadin M, Iqbal J, et al. Dordaviprone Maintenance After Allogeneic HCT for High‐Risk Acute Myeloid Leukemia and Myelodysplastic Neoplasm. American Journal of Hematology. 2026;101(9):2288-2296. doi:10.1002/ajh.70428

BibTeX
@article{Bhatt2026,
  author = {Bhatt, Vijaya Raj and Wichman, Christopher S and Bouska, Alyssa and Ellithi, Moataz and Haddadin, Michael and Iqbal, Javeed and Talmadge, James E and Maness, Lori J and Gundabolu, Krishna},
  title = {Dordaviprone Maintenance After Allogeneic HCT for High‐Risk Acute Myeloid Leukemia and Myelodysplastic Neoplasm},
  journal = {American Journal of Hematology},
  year = {2026},
  volume = {101},
  number = {9},
  pages = {2288--2296},
  doi = {10.1002/ajh.70428}
}
Kostenlos starten →